

Mark Krystal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1871239/publications.pdf>

Version: 2024-02-01

83
papers

3,363
citations

136950

32
h-index

155660

55
g-index

84
all docs

84
docs citations

84
times ranked

2675
citing authors

#	ARTICLE	IF	CITATIONS
1	Amplification, expression, and packaging of a foreign gene by influenza virus. <i>Cell</i> , 1989, 59, 1107-1113.	28.9	469
2	A member of a new repeated sequence family which is conserved throughout eucaryotic evolution is found between the human β^1 and β^2 globin genes. <i>Nucleic Acids Research</i> , 1981, 9, 5931-5948.	14.5	245
3	Orally Active Fusion Inhibitor of Respiratory Syncytial Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 413-422.	3.2	136
4	<i>In Vitro</i> Antiviral Characteristics of HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3498-3507.	3.2	118
5	Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 15366-15371.	7.1	116
6	Prevalence and Clinical Significance of HIV Drug Resistance Mutations by Ultra-Deep Sequencing in Antiretroviral-Naïve Subjects in the CASTLE Study. <i>PLoS ONE</i> , 2010, 5, e10952.	2.5	108
7	Purification and Molecular Structure of RNA Polymerase from Influenza Virus A/PR8. <i>Journal of Biochemistry</i> , 1990, 107, 624-628.	1.7	104
8	Targeting a binding pocket within the trimer-of-hairpins: Small-molecule inhibition of viral fusion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 15046-15051.	7.1	102
9	Pharmacodynamics, Safety, and Pharmacokinetics of BMS-663068, an Oral HIV-1 Attachment Inhibitor in HIV-1-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2012, 206, 1002-1011.	4.0	92
10	Oral Efficacy of a Respiratory Syncytial Virus Inhibitor in Rodent Models of Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 2448-2454.	3.2	73
11	Activity of the HIV-1 Attachment Inhibitor BMS-626529, the Active Component of the Prodrug BMS-663068, against CD4-Independent Viruses and HIV-1 Envelopes Resistant to Other Entry Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4172-4180.	3.2	67
12	Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 895-901.	2.2	63
13	Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 2141-2144.	2.2	61
14	Antiviral activity and molecular mechanism of an orally active respiratory syncytial virus fusion inhibitor. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 289-292.	3.0	61
15	Antiviral Activity, Pharmacokinetics, and Safety of BMS-488043, a Novel Oral Small-Molecule HIV-1 Attachment Inhibitor, in HIV-1-Infected Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 722-728.	3.2	59
16	Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3956-3969.	3.2	58
17	Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 573-581.	3.0	56
18	Structure-activity relationships for a series of thiobenzamide influenza fusion inhibitors derived from 1,3,3-Trimethyl-5-hydroxy-cyclohexylmethylamine. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2002, 12, 3379-3382.	2.2	51

#	ARTICLE	IF	CITATIONS
19	Changes to the HIV Long Terminal Repeat and to HIV Integrase Differentially Impact HIV Integrase Assembly, Activity, and the Binding of Strand Transfer Inhibitors. <i>Journal of Biological Chemistry</i> , 2007, 282, 31186-31196.	3.4	49
20	In Vivo Patterns of Resistance to the HIV Attachment Inhibitor BMS-488043. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 729-737.	3.2	47
21	Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. <i>Proteins: Structure, Function and Bioinformatics</i> , 2015, 83, 331-350.	2.6	47
22	Length heterogeneity in a region of the human ribosomal gene spacer is not accompanied by extensive population polymorphism. <i>Journal of Molecular Biology</i> , 1978, 126, 91-104.	4.2	45
23	Discovery of BMS-955176, a Second Generation HIV-1 Maturation Inhibitor with Broad Spectrum Antiviral Activity. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 568-572.	2.8	45
24	Complementation and analysis of an NP mutant of influenza virus. <i>Virus Research</i> , 1989, 12, 97-111.	2.2	41
25	Respiratory syncytial virus fusion inhibitors. Part 7: Structure-activity relationships associated with a series of isatin oximes that demonstrate antiviral activity in vivo. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 4857-4862.	2.2	39
26	Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 1115-1122.	2.2	38
27	Respiratory syncytial virus fusion inhibitors. Part 6: An examination of the effect of structural variation of the benzimidazol-2-one heterocycle moiety. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4784-4790.	2.2	38
28	Prediction of Virological Response and Assessment of Resistance Emergence to the HIV-1 Attachment Inhibitor BMS-626529 During 8-Day Monotherapy With Its Prodrug BMS-663068. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 7-15.	2.1	38
29	Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 753-757.	2.8	37
30	Respiratory syncytial virus inhibitors. Part 2: Benzimidazol-2-one derivatives. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 1133-1137.	2.2	35
31	pH-Dependent Changes in Photoaffinity Labeling Patterns of the H1 Influenza Virus Hemagglutinin by Using an Inhibitor of Viral Fusion. <i>Journal of Virology</i> , 1999, 73, 1785-1794.	3.4	35
32	Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 299-307.	2.1	34
33	Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents. <i>Drug Discovery Today</i> , 2000, 5, 241-252.	6.4	33
34	Respiratory syncytial virus fusion inhibitors. Part 5: Optimization of benzimidazole substitution patterns towards derivatives with improved activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4592-4598.	2.2	32
35	Synthesis and evaluation of C2-carbon-linked heterocyclic-5-hydroxy-6-oxo-dihydropyrimidine-4-carboxamides as HIV-1 integrase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 717-720.	2.2	32
36	Inhibitors of HIV-1 maturation: Development of structure-activity relationship for C-28 amides based on C-3 benzoic acid-modified triterpenoids. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 1925-1930.	2.2	32

#	ARTICLE	IF	CITATIONS
37	5,6,7,8-Tetrahydro-1,6-naphthyridine Derivatives as Potent HIV-1-Integrase-Allosteric-Site Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1348-1361.	6.4	32
38	Taking aim at a moving target – inhibitors of influenza virus Part 2: viral replication, packaging and release. <i>Drug Discovery Today</i> , 1996, 1, 388-397.	6.4	29
39	An approach to the identification of potent inhibitors of influenza virus fusion using parallel synthesis methodology. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2001, 11, 2393-2396.	2.2	29
40	Triketoacid inhibitors of HIV-integrase: A new chemotype useful for probing the integrase pharmacophore. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2920-2924.	2.2	29
41	Taking aim at a moving target-inhibitors of influenza virus Part 1 : virus adsorption, entry and uncoating. <i>Drug Discovery Today</i> , 1996, 1, 316-324.	6.4	28
42	Entecavir Exhibits Inhibitory Activity against Human Immunodeficiency Virus under Conditions of Reduced Viral Challenge. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1759-1767.	3.2	25
43	C-3 benzoic acid derivatives of C-3 deoxybetulinic acid and deoxybetulin as HIV-1 maturation inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 1757-1770.	3.0	24
44	Solid Phase Synthesis of Novel Pyrrolidinedione Analogs as Potent HIV-1 Integrase Inhibitors. <i>ACS Combinatorial Science</i> , 2010, 12, 84-90.	3.3	23
45	Design, Synthesis, and SAR of C-3 Benzoic Acid, C-17 Triterpenoid Derivatives. Identification of the HIV-1 Maturation Inhibitor 4-((1 <i>R</i> ,3 <i>a</i> <i>S</i> ,5 <i>a</i> <i>R</i> ,5 <i>b</i> <i>R</i> ,7 <i>a</i> <i>R</i> ,11 <i>a</i> <i>S</i> ,11 <i>b</i> <i>R</i> ,13 <i>a</i> <i>R</i> ,13 <i>b</i> <i>R</i>)-3a- ^{6,14} -(1,1-Dioxidothio)acid (GSK3532795, BMS-955176). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7289-7313.	6.4	23
46	Salicylamide inhibitors of influenza virus fusion. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2000, 10, 1649-1652.	2.2	22
47	<i>In Vitro</i> Cross-Resistance Profile of Nucleoside Reverse Transcriptase Inhibitor (NRTI) BMS-986001 against Known NRTI Resistance Mutations. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 5500-5508.	3.2	21
48	Illuminating HIV gp120-ligand recognition through computationally-driven optimization of antibody-recruiting molecules. <i>Chemical Science</i> , 2014, 5, 2311-2317.	7.4	19
49	Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors. <i>PLoS Pathogens</i> , 2016, 12, e1005990.	4.7	19
50	Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naïve patients who participated in the CASTLE Study. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 465-468.	3.0	18
51	Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (A1468002). <i>Clinical Infectious Diseases</i> , 2017, 65, 442-452.	5.8	18
52	The design, synthesis and structure-activity relationships associated with C28 amine-based betulinic acid derivatives as inhibitors of HIV-1 maturation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1550-1557.	2.2	18
53	Expression of antisense RNA fails to inhibit influenza virus replication. <i>Virus Research</i> , 1989, 14, 141-159.	2.2	17
54	Use of microphysiometry for analysis of heterologous ion channels expressed in yeast. <i>Nature Biotechnology</i> , 1996, 14, 880-883.	17.5	17

#	ARTICLE	IF	CITATIONS
55	Novel quinolizidine salicylamide influenza fusion inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 2177-2180.	2.2	17
56	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. <i>PLoS ONE</i> , 2019, 14, e0224076.	2.5	15
57	Benzyl amide-ketoacid inhibitors of HIV-integrase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4886-4890.	2.2	14
58	Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	14
59	GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0187621.	3.2	13
60	A Novel gp41-Binding Adnectin with Potent Anti-HIV Activity Is Highly Synergistic when Linked to a CD4-Binding Adnectin. <i>Journal of Virology</i> , 2018, 92, .	3.4	12
61	Development of antivirals against influenza. <i>Expert Opinion on Investigational Drugs</i> , 1998, 7, 149-165.	4.1	11
62	GSK3732394: a Multi-specific Inhibitor of HIV Entry. <i>Journal of Virology</i> , 2019, 93, .	3.4	11
63	Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the <i>In Vitro</i> Potency of Cabotegravir or Rilpivirine. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, AAC0170221.	3.2	11
64	The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor-Resistant Clinical Isolates. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 75, 52-60.	2.1	10
65	Susceptibility of global HIV-1 clinical isolates to fostemsavir using the PhenoSense® Entry assay. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 648-652.	3.0	10
66	Evaluation of HIV-1 inhibition by stereoisomers and analogues of the sesquiterpenoid hydroquinone peyssonol A. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2192-2196.	2.2	9
67	Exploration of the diketoacid integrase inhibitor chemotype leading to the discovery of the anilide-ketoacids chemotype. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 5818-5821.	2.2	8
68	Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2958-2964.	3.0	8
69	Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc. <i>Aids</i> , 2022, 36, 11-18.	2.2	8
70	Differential effect of modified capped RNA substrates on influenza virus transcription. <i>Virus Research</i> , 1997, 50, 65-75.	2.2	7
71	Development of a photoaffinity label for respiratory syncytial virus inhibitors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2003, 46, 1105-1116.	1.0	7
72	Design and exploration of C-3 benzoic acid bioisosteres and alkyl replacements in the context of GSK3532795 (BMS-955176) that exhibit broad spectrum HIV-1 maturation inhibition. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 36, 127823.	2.2	7

#	ARTICLE	IF	CITATIONS
73	Week 96 Genotypic and Phenotypic Results of the Fostemsavir Phase 3 BRIGHT Study in Heavily Treatment-Experienced Adults Living with Multidrug-Resistant HIV-1. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0175121.	3.2	7
74	Design, synthesis and SAR study of novel C2-pyrazolopyrimidine amides and amide isosteres as allosteric integrase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127516.	2.2	6
75	Design, synthesis and SAR study of bridged tricyclic pyrimidinone carboxamides as HIV-1 integrase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115541.	3.0	6
76	Efavirenz Capsule Sprinkle and Liquid Formulations With Didanosine and Emtricitabine in HIV-1-infected Infants and Children 3 Months to 6 Years of Age. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1355-1360.	2.0	3
77	Novel Bent Conformation of CD4 Induced by HIV-1 Inhibitor Indirectly Prevents Productive Viral Attachment. <i>Journal of Molecular Biology</i> , 2022, 434, 167395.	4.2	1
78	The Genesis and Future Prospects of Small Molecule HIV-1 Attachment Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1366, 45-64.	1.6	1
79	Expression of the influenza virus matrix protein in bacteria. <i>Virus Research</i> , 1988, 11, 40.	2.2	0
80	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. , 2019, 14, e0224076.		0
81	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. , 2019, 14, e0224076.		0
82	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. , 2019, 14, e0224076.		0
83	Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study. , 2019, 14, e0224076.		0